Skip to content

Selfie Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

Selfie Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07222618
Enrollment
300
Registered
2025-10-30
Start date
2025-10-01
Completion date
2028-10-01
Last updated
2025-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS, MS (Multiple Sclerosis), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive

Keywords

multiple sclerosis, MS, digital tool, UCSF

Brief summary

The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired selfie videos in people with multiple sclerosis. The investigators aim to prove the feasibility and validity of monitoring walking changes remotely through a truly patient-centered, low-burden, low-cost approach. The main question this study aims to answer is: do remotely collected walking and speech videos from a mobile phone match the information investigators can gather from an in person visit? Participants will collect 5 selfie videos at baseline, 3 months, 6 months and 12 months (about 15 minutes every 3 months). They will also come in person at baseline, 6 months, and 12 months for in person data collection (about 1 hour per in person visit).

Detailed description

The investigators aim to validate a novel, cost-effective method for real-world assessment using patient-acquired selfie videos. The investigator's preliminary data demonstrate feasibility, validity and utility of this technology, which overcomes limitations of existing digital biomarkers and offers a truly patient-centered, low-burden approach to monitoring and treating diverse people with MS (PwMS). The investigators want to understand the barriers and facilitators to adoption of this approach, as well as the real-world validity and impact of the data generated. This will allow investigators to share the most accessible, generalizable and useful protocols and metrics with the MS community. This approach to digital tool development prioritizes patients and clinicians. Indeed, the investigators leverage a tool used every day by the general population (selfie videos) that recapitulates clinicians' primary examination tool: observing how patients talk and walk. This approach uses the patient's own device (device agnostic: including smartphones sold after 2010, as well as tablets, laptops or desktops with camera capture), without requiring proprietary software or technology, to collect selfie videos - which are ubiquitous in modern life - and provides a link to a secure web portal for simple uploading. The task minimizes burden: it is brief (5 \<1min videos), can be done in individuals' own homes, requires no direct or indirect costs, and therefore is accessible to many diverse patients. Digital biomarkers must demonstrate VALIDITY: sensitivity to subtle change over time, but also relevance to an individual's daily life and function (i.e. veridicality and verisimilitude). Patient selfie videos capture activities relevant in daily life (buttoning a shirt, walking down a hallway, talking about one's morning), across all levels of disability, using assessments that are holistic and that have veridicality and verisimilitude. Furthermore, the metrics show greater sensitivity to change than standard assessments. Overall objective: Validate video selfies as a patient-centered, valid, comprehensive longitudinal data collection method in MS. This approach will be deemed successful if the investigators achieve key metrics informed by implementation science and digital monitoring biomarker validation as necessary for dissemination, which surpass the feasibility, usability or validity of most digital tools currently available for monitoring in MS.

Interventions

None listed

Sponsors

Genentech, Inc.
CollaboratorINDUSTRY
University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patient with MS who is above the age of 18 yrs. Participants who are unable to consent for themselves must have a surrogate decision maker or LAR. * Age \> 18 yrs, EDSS - \<6.5, own a video recording device (smartphone, tablet, camera etc).

Exclusion criteria

* Patient unwilling to participate in the study. Participants unable to consent for themselves who do not have a surrogate decision maker or LAR.

Design outcomes

Primary

MeasureTime frameDescription
Validate key metrics derived from video selfies against the MS Functional Composite (MSFC)1 yearThe investigators will optimize key metrics until they show at least 0.75 correlation coefficient with MSFC z scores, as well as individual domains (walking speed/Timed 25 foot walk, processing speed/Symbol digit modalities test, dexterity/9 hole peg test).

Secondary

MeasureTime frameDescription
Video acquisition protocol usability1 yearThe investigators will explore barriers and facilitators to adoption, and iteratively optimize outreach, instructions, video prompts, camera angles and uploading parameters so diverse PwMS can participate in research and care.
Refine single-domain and composite video metrics1 yearAim 2. Refine single-domain and composite video metrics. Machine learning techniques will generate comprehensive single-domain and holistic metrics of patient functioning that: can be observed asynchronously by clinicians, recapitulate MSFC and EDSS, but are more relevant to daily life than standard metrics.
Validate video metrics' sensitivity to subtle changes over time.1 yearAim 3. Validate video metrics' sensitivity to subtle changes over time. Over 12 months, the investigators will detect subtle worsening in substantially more patients than by existing single domain / global metrics (MSFC, EDSS), informing the tool's utility in measuring PIRA and response to neurorehabilitation, remyelination, and symptom management.

Countries

United States

Contacts

Primary ContactKyra Henderson, Study Coordinator
kyra.henderson@ucsf.edu415-353-8053

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026